ArticleEClinicalMedicine2025
Variability in trends of opioid-related hospital utilization among U.S. Adults, 2016-2021 check.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Emerging Burden of Opioid Poisoning in Brazil, 2019-2025: A Nationwide Epidemiological and Toxicovigilance Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding trends in opioid-related hospital utilization is crucial for informing public health policies; however, existing research is often limited in scope and methodology. This study provides national estimates from 2016 to 2021, emphasizing the variability in trends across different opioid categories and subpopulations. Methods: This study employed a repeated cross-sectional analysis using data from the National Inpatient Sample (NIS) and Nationwide Emergency Department Sample (NEDS). Analyses were performed in two periods: 2016-2019 and 2019-2021 (during the COVID-19 pandemic). Outcomes included rates of opioid-related diagnoses and three types of opioid use disorder-related clinical events: nonfatal opioid overdose, injection drug use-related acute infection, and substance abuse treatment. Further analyses were conducted by opioid category (e.g., heroin and synthetic opioids as a proxy for fentanyl), as well as subgroup analyses based on predefined demographic characteristics, including age, sex, race/ethnicity, socioeconomic status, and geographic location. Findings: Between 2016 and 2019, in the NIS, there was a significant decrease in the rate of opioid-related diagnoses (relative change: -5.4%, 95% Cl: -9.4 to -1.3), nonfatal opioid overdose (-18.4%, -21.7 to -15.0), and substance abuse treatment (-25.1%, -45.9 to -4.3). Conversely, the rate of injection drug use-related acute infection increased significantly (14.4%, 7.3-21.4). In the NEDS, the rates of these outcomes did not change significantly. Notable variations were observed; for instance, in the NIS, the rate of nonfatal synthetic opioids as a proxy for fentanyl overdose increased by 21.1% (11.6-30.5), and heroin-related adverse event or poisoning increased by 51.8% (16.8-86.8) among adults aged 65-84. Between 2019 and 2021, in both the NIS and NEDS, the rate of nonfatal opioid overdose increased significantly (NIS: 8.1%, 3.5-12.7; NEDS: 24.8%, 11.5-38.0), in the NIS, a significant increase was found in the rate of injection drug use-related acute infection (relative increase: 8.2%, 1.2-15.1), while the rates of the other outcomes did not change significantly. Significant variations were also identified; for example, in the NIS, the rate of nonfatal opioid overdose did not show significant change among females, non-Hispanic whites, and adults with higher socioeconomic status. Interpretation: The significant variability in opioid-related hospital utilization trends among U.S. adults underscores the need for careful consideration in the design of future policies, especially during crises. Management strategies should be tailored to specific subpopulations, opioid categories, and OUD-related clinical events to maximize success rates. Funding: Taishan Scholars Program of Shandong Province-Pandeng Taishan Scholars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.